Bayer AG buys herbal medicine company; Novartis is not interested in Actavis;

@FiercePharma: Another pharma deal: Sweden's Recipharm mulls IPO or partial sale, Reuters says. UBS advising. News | Follow @FiercePharma

@EricPFierce: EMA committee backs Bayer's Diane-35 birth control drug, even as off-label acne treatment. Article | Follow @EricPFierce

> Novartis ($NVS) knocked down reports that it was looking at buying generic drugmaker Actavis ($ACT) by publicly saying it was not interested. Report

> Germany's Bayer has bought herbal medicine company Steigerwald Arzneimittelwerk, also a Germany-based company. Report

> The National Institutes of Health (NIH) is looking at how more can be done to fight opioid abuse and is suggesting social media can play a part. Story

> Drugmaker Hikma says it will no longer sell phenobarbital to Arkansas after learning it was being used for executions. Story

> The Biogen Idec ($BIIB) Foundation is making a $250,000 grant to a program in England intended to create an interactive program for young people in Cambridge to learn about genetics. Item 

> Impax Laboratories Inc. ($IPXL) said Friday it is now selling a generic version of the migraine drug Zomig. Story

Medical Device News

@FierceMedDev: Shorter Tryton side branch stent wins CE mark. Article | Follow @FierceMedDev

@MarkHFierce: J&J is leaving the metal hip replacement business behind. Bloomberg broke a good one: Report | Follow @MarkHFierce

 @DamianFierce: Quest buys Humana's toxicology and clinical lab business. News | Follow @DamianFierce

> Thoratec wins FDA nod for HeartMate controller. Report

> Thermedical scores $5.5M in funding for tumor, heart ablation research. Item

> Vascular Solutions sues Boston Scientific for 'blatant' patent infringement. News

Biotech News

@FierceBiotech: PPD's BioDuro opens Shanghai discovery lab. FierceCRO story | Follow @FierceBiotech

@JohnCFierce: Amgen, Novartis aim to fuel biotech startups in alliance with Atlas Venture. Report | Follow @JohnCFierce

@RyanMFierce: PTC, bluebird join the IPO frenzy in biotech with genetic therapies. Story | Follow @RyanMFierce

> Sanofi balks on jobs promises at R&D site in Toulouse. Report

> Novo Nordisk completes PhIII hemophilia trial with positive results. Item

> AbbVie, Galapagos extend JAK1 pact into Crohn's disease with $50M carrot. News

And Finally... In its official rejection of a $5.7 billion buyout offer from Royalty Pharma, Irish drug company Elan said Royalty made its bid after first suggesting Elan buy Royalty out. Story

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.